Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Cash from Investing Activities (2018 - 2025)

UroGen Pharma (URGN) has disclosed Cash from Investing Activities for 8 consecutive years, with $27.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 54.28% year-over-year to $27.7 million, compared with a TTM value of $61.6 million through Dec 2025, up 398.64%, and an annual FY2025 reading of $61.6 million, up 398.64% over the prior year.
  • Cash from Investing Activities was $27.7 million for Q4 2025 at UroGen Pharma, down from $31.4 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $60.6 million in Q4 2024 and bottomed at -$106.8 million in Q3 2024.
  • Average Cash from Investing Activities over 5 years is $2.3 million, with a median of $9.9 million recorded in 2021.
  • The sharpest move saw Cash from Investing Activities surged 2563.58% in 2023, then tumbled 26720.95% in 2024.
  • Year by year, Cash from Investing Activities stood at $9.1 million in 2021, then soared by 153.24% to $23.1 million in 2022, then plummeted by 149.09% to -$11.3 million in 2023, then soared by 634.39% to $60.6 million in 2024, then plummeted by 54.28% to $27.7 million in 2025.
  • Business Quant data shows Cash from Investing Activities for URGN at $27.7 million in Q4 2025, $31.4 million in Q3 2025, and $28.4 million in Q2 2025.